Results 21 to 30 of about 45,696 (262)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +2 more sources

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +2 more sources

Ceftazidime-avibactam induced renal disorders: past and present

Frontiers in Pharmacology
With the increasing prevalence of multidrug-resistant Gram-negative bacterial pathogens worldwide, antimicrobial resistance has become a significant public health concern. Ceftazidime-avibactam (CAZ-AVI) exhibited excellent in vitro activity against many carbapenemase-producing pathogens, and was widely used for the treatment of various complicated ...
Yanrong Shi, Jichao Wu, Wei Mi, Xusheng Zhang, Xiuli Ren, Chengwu Shen, Cuicui Lu   +6 more
openaire   +4 more sources

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review

New Microbes and New Infections
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian   +6 more
doaj   +2 more sources

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

PLoS ONE
BackgroundGlobal surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level
Shulong Zhao, Lin Ye, Shuang Song, Jingfang Sun, Jinfeng Xu, Fei Jiang, Haiquan Kang   +6 more
doaj   +2 more sources

Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.

PLoS ONE
NDM-producing carbapenem-resistant bacterial infections became a challenge for clinicians. Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections.
Salman Khan, Arghya Das, Deepali Vashisth, Anwita Mishra, Ashima Jain Vidyarthi, Raghav Gupta, Nazneen Nahar Begam, Babita Kataria, Sushma Bhatnagar   +8 more
doaj   +2 more sources

Ceftazidime-avibactam [PDF]

Revista Española de Quimioterapia, 2021
Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire   +2 more sources

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +2 more sources

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Frontiers in Microbiology, 2021
Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman   +8 more
doaj   +1 more source

Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]

The Lancet Infectious Diseases, 2016
One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli, Jon, Armstrong, Paul, Newell, Greg, Stone, Angela, Wardman   +4 more
openaire   +5 more sources